Synonym
Product Category
Product Code
CAS Number
MDL Number
Pubchem CID
Reaxys RN
Tipiracil-trifluridine Mixture, Trifluridine-tipiracil hydrochloride mixture
API & Intermediates
KAPI3F05
733030-01-8
TAS 102 (also known as TAS-102, Tipiracil-trifluridine Mixture, Trifluridine-tipiracil hydrochloride mixture) is an orally active thymidine phosphorylase inhibitor and antimetabolite agent comprised of trifluridine, a thymidine-based nucleoside analogue, and tipiracil, a potent thymidine phosphorylase inhibitor. It is used for the treatment of metastatic colorectal cancer.
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. [1]
Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. [2]
Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. [3]
TAS-102: more than an antimetabolite. [4]
Trifluridine/Tipiracil: A Review in Metastatic Colorectal Cancer. [5]
Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer under oral trifluridine-tipiracil (TAS-102) chemotherapy. [6]
References:
[1] T.Emura, et al, Int. J. Oncol., 2004, 25(3), pp 571-578.
[2] D.S.Hong, et al, Cancer, 2006, 107(6), pp 1383-1390.
[3] O.H.Temmink, et al, Cancer Sci., 2007, 98(6), pp 779-789.
[4] G.J.Peters, et al, Lancet Oncol., 2012, 13(12), pp e518-e519.
[5] C.B.Burness, et al, Drugs, 2016, 76(14), pp 1393-1402.
[6] M.Kimura, et al, Pharmazie., 2017, 72(1), pp 49-52.
Signal Word
Hazard Statements
Precautionary Statements
HS Code
RIDADR
Legal Information
Not classified as a dangerous goods
NONH for all modes of transport
Sales restrictions may apply.
Please inquire for pricing and availability of this product by writing email to sales@kumidas.com.